"Ozempic pill" searches are asking about a product that exists but is not what most people picture. There is no tablet that does what a weekly Ozempic pen does, milligram for milligram. There is a tablet sold under the Ozempic name — and it is the successor to Rybelsus, not a new form of the injection.
This page reads the shared RYBELSUS and OZEMPIC tablets prescribing information (Novo Nordisk, NDA 213051, SPL version 14, published on DailyMed 19 August 2026), the WEGOVY label (effective 18 June 2026) and FDA's drug shortage database, all read on 24 September 2026. How oral semaglutide gets absorbed at all, and why the two tablet ranges use different milligrams for the same exposure, is on our oral GLP-1 page; this page does not repeat it.
Nothing here tells anyone which product to take or how. Where the label gives instructions, they are reported as what the label says.
What the Ozempic pill is
| Ozempic tablets | Rybelsus | |
|---|---|---|
| Molecule | semaglutide | semaglutide |
| Strengths | 1.5 mg, 4 mg, 9 mg | 3 mg, 7 mg, 14 mg |
| Shape (label description) | round | oval |
| Inactive ingredients | magnesium stearate, SNAC | magnesium stearate, microcrystalline cellulose, povidone, SNAC |
| Approval file | NDA 213051 | NDA 213051 |
| Indications | type 2 diabetes: glucose control; cardiovascular risk reduction | same |
| Status (FDA shortage database, 24 Sep 2026) | — | "To Be Discontinued", all three strengths, dated 2026-06-04 |
One label covers both, one application covers both, and the uses are identical. What changes is the tablet and its milligram scale. Our compounded semaglutide page recorded the discontinuation notice when it first appeared; it is unchanged three and a half months later.
Switching: what the label maps, and what it leaves out
The label's section 2.3 sets out the move between the two tablets, and section 2.4 the move from the injection. Reported as the label states them:
| From | To | Label condition |
|---|---|---|
| Rybelsus 7 mg | Ozempic tablets 4 mg | Not during the first 30 days; start the next day |
| Rybelsus 14 mg | Ozempic tablets 9 mg | Same |
| Ozempic injection 0.5 mg | Rybelsus 7 or 14 mg, or Ozempic tablets 4 or 9 mg | One week after the last injection |
| Ozempic injection 1 mg or 2 mg | — | No route in the label |
| Rybelsus 3 mg / Ozempic tablets 1.5 mg | — | Starting doses; the label says they are "not effective for glycemic control" |
Two things follow from the label's own wording. First, the starting tablets are not interchangeable either: the label says not to switch during the initiation phase at all. Second, anyone on the 1 mg or 2 mg injection — the doses many people reach — has no tablet equivalent printed anywhere in this label. That does not mean a switch cannot happen; it means the label gives no conversion, so it is a prescriber's judgement rather than a table lookup.
The Wegovy tablet the label describes in the same words
Put the two Novo Nordisk labels side by side and a detail appears that neither mentions:
| Tablet | Ozempic tablets label | Wegovy label |
|---|---|---|
| 1.5 mg | round, debossed "1.5" / "novo"; magnesium stearate + SNAC | round, debossed "1.5" / "novo"; SNAC + magnesium stearate |
| 4 mg | round, "4" / "novo" | round, "4" / "novo" |
| 9 mg | round, "9" / "novo" | round, "9" / "novo" |
| 25 mg | — | oval, "25" / "novo" |
| Bottle NDC (1.5 / 4 / 9 mg) | 0169-1715-30 · 0169-1704-30 · 0169-1709-30 | 0169-4415-31 · 0169-4404-31 · 0169-4409-31 |
| Absolute bioavailability | 1% to 2% | approximately 1% to 2% |
| Indication | type 2 diabetes | weight reduction and cardiovascular risk reduction |
At three strengths the two labels print the same description, the same two inactive ingredients and the same bioavailability range. What differs is the bottle, its code, the indication — and the ceiling: Wegovy's escalation continues to a 25 mg tablet, which has no Ozempic counterpart, just as the Wegovy pen goes to doses the Ozempic pen does not.
The Wegovy label also states that using Wegovy with "other semaglutide-containing products" is not recommended — so the two are never meant to be taken together.
We are not claiming the tablets are the same product; the labels do not say so, and manufacturing detail beyond the label is not public. What the labels support is narrower and still useful: the difference between an "Ozempic pill" and a "Wegovy pill" at 1.5, 4 or 9 mg is, on the printed record, the indication and the packaging — which is also what decides insurance coverage, as our insurance coverage page explains. The Wegovy tablet has its own record on our pill versus injection page.
What the tablet trials showed
The label's clinical section rests on eight trials of semaglutide tablets, all run on the Rybelsus formulation (the label's pharmacokinetic study is what links it to the Ozempic tablets). The one that added the cardiovascular indication:
| Tablet cardiovascular outcomes trial (9,650 adults) | Placebo | Semaglutide tablets 14 mg | Hazard ratio (95% CI) |
|---|---|---|---|
| Heart attack, stroke or cardiovascular death | 13.8% | 12.0% | 0.86 (0.77–0.96) |
| Cardiovascular death | 6.6% | 6.2% | 0.93 (0.80–1.09) |
| Non-fatal heart attack | 5.2% | 4.0% | 0.74 (0.61–0.89) |
| Non-fatal stroke | 3.3% | 3.0% | 0.88 (0.70–1.11) |
The reduction came mainly from non-fatal heart attacks; cardiovascular death did not clearly differ. The injection's equivalent trial is set out on our Ozempic side effects page, which also covers the retinopathy and low-blood-sugar warnings the tablet label shares.
Two label details that matter more for a tablet
- Thyroid medicine. In the label's interaction studies, total thyroxine exposure rose 33% (90% CI 1.25–1.42) when levothyroxine was taken with semaglutide tablets. For oral drugs with a narrow therapeutic index or that need clinical monitoring, the label says to "consider increased clinical or laboratory monitoring"; what that means for a given person is for the prescriber.
- The routine is part of the dose. Absorption was higher with less water and with a longer wait before eating, per the label's pharmacokinetic studies — which is why the label's administration conditions (empty stomach, up to 4 ounces of water, 30 minutes before food, drink or other tablets) read as they do. Semaglutide stays in the circulation for about five weeks after the last tablet.
What this page cannot tell you
- Price. Tablet prices and savings programmes change often and are tracked, dated, on our GLP-1 pills cost page.
- Whether a particular switch suits a particular person. The label's table is a starting point for prescribers, not a conversion anyone should apply alone.
- When Rybelsus bottles stop being available. The shortage database gives a status, not a last-supply date.
Anyone on Rybelsus or Ozempic who has questions about switching should take them to their prescriber or pharmacist. The full register of approved oral GLP-1 tablets is on our oral GLP-1 page.
Sources
- RYBELSUS and OZEMPIC (semaglutide) tablets, prescribing information, Novo Nordisk, NDA 213051, SPL version 14 — DailyMed setid 27f15fac-7d98-4114-a2ec-92494a91da98, read 2026-09-24: sections 1, 2.1–2.4, 3, 11, 12.3, 14.4 and 16.
- WEGOVY (semaglutide) injection and tablets, prescribing information, Novo Nordisk, effective 2026-06-18 — DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, read 2026-09-24: sections 3, 11 and 16.
- FDA drug shortage database, semaglutide entries, via openFDA, read 2026-09-24.
- Tablet cardiovascular outcomes trial NCT03914326 (label section 14.4).